Replies to post #30291 on Rock Creek Pharmaceuticals Inc. (fka RCPIQ)

[1manband]

Since MYMD Pharma will eventually replace RCPIQ

No, it won't.

Geez, does anyone understand the even most basic information about bankruptcy laws?

Chapter 7 is AUTOMATIC LIQUIDATION. The stock is finished. There will be no merger, and RCPIQ is not a shell. Anyone holding RCPIQ shares will lose 100% of their investment, which can happen at any time without any warning. The ticker will disappear.

To claim otherwise is complete BS.

[Value_Investor]

With such important Bio-Tech Patent RCPIQ will hit its recent high 0.02 again easily once it is Reverse-Merged with its related private company MYMD! Hopefully I could exchange all my RCPIQ shares for the New stock MYMD very soon...

So any Dirt Cheap price at 0.0024 ~ 0.0006 are Huge discount comparing to the target price 0.02! If we buy 5M shares at current basement price levels (meager 7.5K cost at the average price 0.0015) then those shares will be worthy $100K at 0.02!

[knuts4oe]

MYMD PHARMA PART 2 "About Us"
"Work performed at the Johns Hopkins School of Medicine, recently published in The Journal of Immunology, has shown that MYMD-1 specifically targets subsets of T lymphocytes called effector T cells by reducing their activity. Effector T cells are involved in mediating a broad spectrum of autoimmune diseases. The studies further showed that MYMD-1 has a broad spectrum effect on the immunometabolic system including, suppressing in vitro the production of the pro-inflammatory cytokine TNF-alpha by effector T helper 1 T lymphocytes (Th1 cells), reducing nitrite and increasing hydrogen sulfide. Multiple mouse disease models have demonstrated that MYMD-1 decreased the incidence and severity of MS, and significantly extended longevity and reversed signs of aging."

"MYMD-1 is a small molecule with a benign safety profile as demonstrated in pre-clinical studies. Phase 1 human safety and dosing trials are scheduled for completion in 2019"

"As an immunometabolic regulator, MYMD-1 uniquely targets the rate of cellular oxidation as the underlying cause (as opposed to the symptom) of many currently uncured diseases. Accordingly, the therapeutic scope of our lead candidate is being expanded through ongoing preclinical studies focused on additional age-related diseases, virtually all autoimmune diseases, Alzheimer's disease, various cancers and heart disease."